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Summary 
 
Integrase (IN) is one of the most important enzymes in the replication 
of the HIV-1 virus, as it integrates viral DNA (vDNA) into the genome of the 
host cells. However, recent studies have suggested a new surprising role of 
IN in HIV-1 maturation. If IN is inhibited either by mutations or by allosteric 
integrase inhibitors (ALLINIs), viral ribonucleoprotein complexes (vRNPs)  
are often eccentrically localized outside of the capsid (CA). Such viral 
particles are non-infectious and are blocked at an early stage of the reverse 
transcription in the target cells, as a result of premature degradation of IN 
and viral RNA (vRNA) genome, together with the spatial separation of 
reverse transcriptase (RT) from vRNA.  
IN directly binds the vRNA genome in virions by its surface exposed 
lysine residues, exhibiting a distinct preference for selected vRNA structural 
elements. In this way, IN provides nucleation points by bridging separate 
RNA molecules, promoting the effective compaction of vRNPs. These 
interactions then ensure the proper packaging of vRNPs inside the CA.  
Even though the mechanism of action of ALLINIs, an emerging class of 
anti-HIV drugs, is still not fully understood, it seems that they mostly act by 
blocking the IN-vRNA interaction, which results in aberrant non-infectious 
particles. 
This non-catalytic role of IN enables the understanding of the HIV-1 
maturation process in greater detail, which can be successfully used in the 
development of new drugs, such as ALLINIs. However, a lot of research still 
needs to be done, as there is a lot of detail in this IN-driven maturation 
process that still needs to be explained. 
 
Keywords: HIV-1, integrase, maturation, vRNPs, vRNA packaging, IN-
vRNA interactions, ALLINIs 
 
 
 
      
 
 
Sažetak 
Integraza (IN) je jedan od najvažnijih enzima u replikaciji HIV-1 virusa, 
budući da integrira virusnu DNA (vDNA) u genom stanice domaćina. 
Međutim, novije studije su predložile novu, iznenađujuću ulogu IN u 
sazrijevanju HIV-1. Ukoliko je IN inhibirana bilo mutacijama bilo alosteričkim 
inhibitorima integraze (ALLINI-ji), virusni ribonukleoproteinski kompleksi 
(vRNP-ovi) su često acentrično lokalizirani izvan kapside (CA). Ove čestice 
nisu infektivne i blokirane su u ranoj fazi reverzne transkripcije u ciljnim 
stanicama, kao rezultat preuranjene degradacije IN i virusnog RNA (vRNA) 
genoma, zajedno s prostornom odvojenošću reverzne transkriptaze (RT) od 
vRNA.  
IN izravno veže vRNA u virionima putem svojih površinski izloženih 
lizinskih ostataka, pokazujući izrazite preference za određene vRNA 
strukturne elemente. Na ovaj način IN stvara nukleacijske točke, 
premošćujući odvojene RNA molekule i unaprjeđujući učinkovito zbijanje 
RNP-ova. Ove interakcije osiguravaju ispravno pakiranje vRNP-ova unutar 
CA. 
Iako mehanizam djelovanja ALLINI-ja, skupine anti-HIV lijekova u 
nastajanju, još uvijek nije do kraja razjašnjen, čini se da oni većinski djeluju 
blokirajući IN-vRNA interakcije, što rezultira abnormalnim neinfektivnim 
česticama. 
Ova nekatalitička uloga IN omogućava detaljnije shvaćanje procesa 
sazrijevanja HIV-1, što se može uspješno upotrijebiti u razvoju novih 
lijekova poput ALLINI-ja. Međutim, potrebno je provesti još mnogo 
istraživanja jer puno detalja u ovom IN potpomognutom procesu 
sazrijevanja još uvijek mora biti razjašnjeno.    
 
Ključne riječi: HIV-1, integraza, sazrijevanje, vRNP-ovi, pakiranje vRNA, IN-
vRNA interakcije, ALLINI-ji 
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1. Introduction 
The term “human immunodeficiency virus (HIV)” reffers to two species, 
HIV-1 and HIV-2, belonging to the group of retroviruses and subtype of 
lentiviruses, which can cause the acquired immunodeficiency syndrome – 
AIDS [1]. Although these two viruses are related, there are many biological 
differences including their genetic and structural elements, time of 
replication and progression of infection. HIV-1 is responsible for the majority 
of the AIDS related infections, by infecting macrophages, dendritic cells and 
especially CD4+ T-cells. Today, there are around 37 million people globally 
living with HIV-1, and every year almost 2 million people become newly 
infected, with approximately 1 million people dying from AIDS-related 
diseases [2]. As almost 40% of all people living with HIV-1 still does not 
have access to antiretroviral therapy [2], this epidemic poses one of the 
major world health problems. 
HIV-1 is present only in certain body fluids, such as blood, semen, pre-
seminal fluid, rectal fluids, vaginal fluids, and breast milk. For transmission 
to occur, these fluids must come in contact with mucous membranes, which 
are found inside the rectum, vagina, penis, and mouth, or with the damaged 
tissue. Therefore, the virus is primarily transmitted in three ways: sexually, 
vertically from a mother to a child (during pregnancy, birth or 
breastfeeding), and by direct blood contact with an infected persons’ blood 
[3]. The HIV-1 diagnosis is mostly based on tests for HIV-1 antibodies, 
which are detected by using ELISA together with the PCR and Western blot 
techniques. These tests are today inexpensive and extremely accurate [4] 
[5]. 
The majority of the people will, without receiving antiretroviral therapy, 
develop AIDS symptoms in five to ten years after the infection, with the 
average lifespan being eleven years [6].   
The first phase of HIV-1 infection, the acute phase, starts days to weeks 
upon the infection and lasts only 1-2 weeks. The patient experiences 
mononucleosis-like or flu-like symptoms, such as fever, headache, 
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lymphadenopathy, and rash. In this stage, HIV multiplies rapidly, destroying 
the CD4+ T-cells that try to fight off the infection. Because of the nonspecific 
nature of these symptoms, they are often misdiagnosed for the more 
common infectious diseases with the same or similar symptoms [5, 7].  
The second phase is called the chronic HIV infection, but also known as 
asymptomatic HIV infection or clinical latency. During this phase, HIV 
continues to multiply in the body but at the very low levels, as a strong 
immune defense response reduces the number of viral particles in the 
bloodstream at the end of the acute phase. The duration of this stage is 
approximately 8 years, during which the infected person does not experience 
any symptoms, but can spread the virus [5, 7]. 
The third phase is known as AIDS, and it is the final stage of  
HIV- casused disease progression, when the immune system is already very 
weakened and not able to fight off opportunistic infections and cancers. AIDS 
is diagnosed when the concentration of CD4+ T-lymphocytes is lower than 
200 cells per mm3 of blood, making the organism vulnerable to various 
opportunistic infections, such as pneumocystis pneumonia and candidal 
esophagitis, or cancers, such as Kaposi's sarcoma, Burkitt's lymphoma or 
cervical cancer. Without receiving antiretroviral therapy, people with AIDS 
usually survive about three years [5] [7].  
HIV evolved from the simian immunodeficiency virus (SIV), which 
infects primates residing in the west and central Africa. As SIV is a relatively 
weak virus for humans and can be easily defeated by the human immune 
system, the most common explanation is that SIV evolutionary developed 
into HIV to successfully replicate in humans, and therefore secured its 
existence. The mass movement of people in the 20th century helped the 
virus to spread out of Africa, and it was first discovered and described in the 
mid-1980s by two independent research groups under the lead of Robert 
Gallo and Luc Montagnier [8]. 
The first HIV antiretroviral drug was zidovudine, which acts as a reverse 
transcriptase nucleoside inhibitor, approved by the US Federal Drug Agency 
(FDA) in 1987. However, only with the introduction of highly active 
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antiretroviral therapy (HAART) in 1996., which combined reverse 
transcriptase inhibitors with protease inhibitors, the AIDS-related death rates 
started to decline by 60-80 % [9]. Since then, HIV therapy became very 
efficient, causing HIV infection to become a chronic disease that progresses 
into AIDS very slowly. Today, HAART therapy is mostly administered in the 
fixed-dose combination, combining several antiretroviral drugs into one pill. 
These drugs are divided into several classes, depending on which viral 
enzyme or on which viral replication step they act: protease inhibitors, 
coreceptor antagonists, nucleoside and non-nucleoside reverse transcriptase 
inhibitors, fusion inhibitors and integrase inhibitors [10]. 
HIV infected patients can nowadays expect to achieve nearly normal life 
expectancy if taking antiretroviral therapy, which causes long viral 
suppression. However, they need to take lifelong medication, which has its 
side effects, such as causing higher rates of kidney, liver, cardiovascular or 
neurological diseases [11]. This has stimulated further research towards 
enhancing already existing therapy and finding new, even more efficient 
drug targets. One of such targets is the HIV-1 enzyme integrase (IN), for 
which the new research suggests that it is not only involved in the 
integration of HIV-1 genome inside the host cell genome, but also in the 
maturation of new viral particles. Even though it seemed that the replication 
and maturation cycle of HIV-1 is very well observed and known, recent 
discoveries, like in the case of IN, suggest there is still much to learn about 
these processes. This is calling for a need to revise our current knowledge 
about HIV-1 replication and maturation cycles introducing the new research 
data, and to think about the possible future applications of such discoveries, 
especially in the development of new drugs and in the treatment of patients. 
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2. Aim of the thesis 
While the structure and catalytic function of IN are very well known, 
recent studies suggest that viral DNA integration is not the only role of IN, 
but that it is also involved in the viral particle maturation. Allosteric 
integrase inhibitors (ALLINIs), a new promising class of antiretroviral drugs, 
can block the integration steps, but can also block the interactions between 
the IN and viral RNA (vRNA) genome, causing the viral particles to be non-
infectious. This strongly suggests that IN can be crucial for the proper HIV-1 
maturation and its infectivity. The focus of this thesis is to discuss this newly 
found role of IN in virion maturation and how it can be used in the 
development of antiretroviral therapy of HIV-1 patients. 
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3. Discussion 
3.1 Structure and genome of HIV-1 
HIV-1 virion has spherical shape, with a diameter of approximately 100-
150 nm (Figure 1). Two copies of positive single-stranded RNAs, which make 
the HIV-1 genome, are found inside the capsid (CA) made of viral p24 
protein. The RNA molecules are tightly bound to the nucleocapsid (NC) p7 
proteins. Two enzymes needed for the replication and development of the 
virion, reverse transcriptase (RT) and integrase (IN), are also inside the CA. 
The CA is surrounded by a matrix composed of p17 viral protein, which 
ensures the integrity of the virion. The third important enzyme in the 
replication, protease (PR), can be found between the CA and the matrix. The 
matrix is encircled by the viral envelope, mostly composed of host cell 
proteins and a lipid bilayer, as it is a part of the host cell membrane taken 
during the budding process of new viral particles. The envelope glycoprotein 
complex, which is essential for virus attachment to the recpetor on a target 
cell and entry of virus into the cell, consists of glycoprotein 120 (gp120) cap 
and a stem made of three glycoprotein 41 (gp41) molecules [5] [12]. 
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Figure 1: HIV-1 structure. Two RNA molecules bound to the nucleocapsid (NC)  proteins are found 
inside the capsid (CA), which is surrounded by the matrix and the viral envelope containing 
glycoprotein complexes. The enzymes integrase (IN) and reverse transcriptase (RT) are found inside 
the CA, while protease (PR) is outside of the CA. The work of Thomas Splettstoesser 
(www.scistyle.com). 
 
Two genomic RNA molecules are 9749 nucleotides long, containing the 
5’ CAP and 3’ poly-A tail, together with the long terminal repeats (LTR) on 5’ 
and 3’ end (Figure 2). There are three main genes which code for main viral 
structural proteins and enzymes: 
1) Gag gene encodes a polyprotein which is later processed by PR giving 
structural proteins p7 (nucleocapsid protein), p17 (matrix protein) and 
p24 (capsid protein) 
2) Pol gene encodes viral enzymes PR, RT and IN 
3) Env gene encodes the glycoproteins gp120 and gp41  
 
There are two most important regulatory genes: Tat and Rev. Tat gene 
regulates the transcription of viral DNA in the host cell, while Rev regulates 
the gene expression of viral proteins, which will be later explained during the 
description of the HIV-1 replication cycle. The rest of the genes code for the 
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accessory regulatory proteins: vpr, vif, nef, and vpu, which assist in the viral 
replication [5]. 
 
 
Figure 2: HIV-1 genome containing the structural genes (gag, pol, env), regulatory genes (tat and 
rev), and accessory regulatory genes (vpr, vif, nef, vpu). The work of Thomas Splettstoesser 
(www.scistyle.com). 
      
3.2 HIV-1 replication cycle  
The replication cycle of HIV-1 inside CD4+ T-lymphocytes can be 
divided into several steps (Figure 3): 
In the first step, HIV-1 enters the cell by binding to the CD4 receptor on 
the T-cell surface, using the viral envelope glycoprotein gp120. This gp120 - 
CD4 interaction drives the conformational change of the viral envelope, 
enabling gp120 to bind to the T-cell coreceptors, CCR5 and CXCR4. In the 
next step, viral gp41 penetrates the cell membrane and brings the virus 
closer to the cell. When the viral envelope is found in the close proximity to 
the T-cell, it fuses with the cell membrane. Following the fusion of the 
envelope with the membrane, the CA containing two single-stranded vRNA 
and key viral enzymes (RT, IN and PR) is injected in the cell [5].  
In the second step, the HIV-1 CA is uncoated and the RT copies the 
vRNA into the complementary two-stranded viral DNA molecule (vDNA). This 
process is extremely error-prone due to the poor proofreading potential of 
the RT, resulting in the great number of HIV-1 mutations. After the process 
of reverse transcription is completed, the RT degrades viral RNA molecules 
[5] [12]. 
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In the third step, the IN binds to the vDNA, forming a complex known 
as intasome. The intasome is then transferred in the nucleus through a 
nuclear pore, where the IN integrates the vDNA in the host cell chromosome. 
This process will be described in greater detail later in the text. 
In the fourth step, integrated vDNA is transcribed by host RNA II 
polymerase and various cell’s transcription factors, such as NF-kB [13], to 
generate pre-messenger RNA (pre-mRNA), some of which undergo the 
splicing process to give mature mRNA. These mature mRNAs, which contain 
the Rev and Tat gene, are transported from the nucleus to the ribosomes for 
the translation. Produced Tat protein significantly enhances the transcription 
efficiency by recruting cell’s transcription factors, while the Rev protein acts 
as an adaptor that returns to the nucleus and binds longer and larger mRNAs 
that do not undergo the splicing process and can not be alone exported from 
the nucleus, i.e. unspliced genomic RNA (gRNA). When Rev is bound to 
gRNAs, they are successfully exported in the cytoplasm. Some gRNA act as 
complete copies of the viral genome, while others contain genes from which 
new viral structural proteins and enzymes are synthesized [14]. The results 
of gRNA translation are long polypeptide chains containing several viral 
enzymes necessary for further viral development. These enzymes need to be 
cut from the polypeptide chain in the reaction catalyzed by protease to 
become functional [12]. 
In the fifth step, Gag proteins bind to the viral RNA copies and pack 
them into new viral particles that are transported to the cell membrane, 
where the particle binds to the internal side of the membrane. Env 
polyprotein gp160 is then processed by furin, an enzyme inside the Golgi 
Apparatus, giving rise to gp41 and gp120 glycoproteins. These glycoproteins 
are then also transported to the cell membrane, where gp41 acts as an 
anchor for gp120 inside the lipid bilayer. Viral particles then bud from the 
host cell, taking a part of the cell membrane as their viral envelope, thus 
destroying the infected T-lymphocyte. A newly formed virion is still immature 
and not infectious until all Gag polyproteins are processed by PR, forming 
the matrix, CA and NC proteins [12]. When this processing is done, a new 
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HIV-1 viral particle becomes infectious and can attack new cells, repeating 
the replication cycle. 
 
 
 
Figure 3: HIV-1 replication cycle. The cycle starts with the viral entry into the host cell, followed by 
the reverse transcription and integration of the viral cDNA into the host cell genome. Using the host 
cell’s transcription factors, viral genes are transcribed and translated, forming new viral particles, 
which bud from the cell. Taken from Pasternak et al. 2013. [14]. 
      
      
3.3 Integrase structure and catalytic function 
HIV-1 integrase is a 32 kDa protein (288 amino acids) and a member of  
polynucleotidyl transferases family. The protein can be divided into three 
functionaly distinct domains (Figure 4): the N-terminal domain, the catalytic 
core domain, and the C-terminal domain [15]. 
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The N-terminal domain (NTD) is a small dimer that is predominantly 
composed of hydrophobic residues, containing 50 amino acids (residues 1-
50) and a zinc-binding HHCC (a pair of His and Cys residues) motif. Binding 
of zinc to this motif enhances the multimerization of IN into an active 
tetramer form [16], which is required for optimal enzymatic activity. 
On the other hand, the catalytic core domain (CCD) is a spherical dimer 
composed of 162 amino acids (residues 51-212) which contains a highly 
conserved DD(35)E motif with the key residues of the IN active site: Asp64, 
Asp116, and Glu152. These three residues coordinate divalent metal ions of 
magnesium and manganese, which play a key role in the phosphodiester 
cleavage and bond formation reactions that are catalyzed during the 
integration process [15]. 
The C-terminal domain (CTD) is a dimer composed of 75 amino acids 
(residues 213-288) responsible for the non-specific binding of DNA during 
the integration process. It is considerably less conserved among retroviral 
INs than the two other domains [17]. 
 
 
 
Figure 4: Schematic structure of HIV-1 IN, composed of N-terminal domain, catalytic core and C-
terminal domain, each of them having a different role. Taken from Esposito and Craigie 1999. [17] 
      
The role of IN in the vDNA integration is well described and 
documented. First, an IN tetramer binds both vDNA ends forming the 
intasome complex. The intasome then associates with the cellular protein 
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LEDGF/p75, which guides the intasome to the specific chromatin sites and 
enhances the efficiency of the integration process [18, 19].  
The integration reaction occurs in three steps (Figure 5). First, in the 
step known as the 3' end processing, two nucleotides are removed from the 
vDNA 3' ends by a hydrolytic cleavage process, leaving two free 3'-OH 
groups. In the second step, known as the DNA strand transfer, these two 3'-
OH groups are used to perform a nucleophilic attack on a pair of 
phosphodiester bonds separated by 5 bp in the target DNA, forming the 
integration intermediate where the vDNA 3' ends are covalently bound to the 
target DNA. In the final step, cellular enzymes repair the integration 
intermediate by removing the two unpaired nucleotides at each 5' end of the 
vDNA, followed by gap filling and ligation [17, 20]. 
      
 
 
Figure 5: Steps of vDNA integration: 3’ end processing removes the two nucleotides from the vDNA 3’ 
ends and is followed by the DNA strand transfer, in which the two free OH groups attack the 
phosphodiester bond in the target DNA, resulting in the integration intermediate. Finally, cellular 
enzymes repair the intermediate, ensuring the integration of vDNA in the host cell’s genome. Taken 
from Craigie 2012. [20] 
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3.4 Integrase mutations 
Surprisingly, IN mutagenesis screens have shown that various 
mutations in the IN coding region impair not only the integration but also 
other processes involved in HIV-1 replication. Based on the observed 
phenotypes, the IN mutations have been grouped into two general classes: 
class I mutations impair integration, while class II mutations affect reverse 
transcription, particle assembly, and maturation [21]. Some of these class II 
mutations result in severe morphological defects in HIV-1 virions, especially 
during virion maturation. 
The HIV-1 virion maturation starts when PR cuts the long Gag-encoded 
polyproteins. The cleaved NC proteins from Gag polyprotein then bind with 
the vRNA inside the conical CA, thus forming the viral ribonucleoprotein 
complexes (vRNPs). The majority of the proposed virion maturation models 
have therefore been focused on the proteolytic cleavage processes. 
However, in particles with the class II IN mutations, the vRNPs are 
eccentrically localized outside of the CA, leaving it empty. Such particles are 
noninfectious, and are blocked at an early stage of reverse transcription in 
the cells they attack [22]. These findings first revealed that IN has an active 
role in the encapsidation of the vRNA inside the mature conical CA. 
 
3.5 Allosteric integrase inhibitors (ALLINIs) 
The early class of IN inhibitors, IN strand transfer inhibitors (INSTIs), 
inhibit DNA strand transfer activity, as they bind to the intasome at the IN 
active site and remove the terminal deoxyadenosine of vDNA, which would 
otherwise be used by IN to cut specific chromatin sites in the target cell 
[23]. A new class of IN inhibitors which has emerged only recently, allosteric 
IN inhibitors (ALLINIs), function differently. Their ability to inhibit the 
interaction between the IN and the cellular integration cofactor LEDGF/p75 
was long considered to be the main mode of their action. 
However, it was only recently discovered that these compounds also 
affect the late stage of HIV-1 replication, independently of LEDGF/p75 
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inhibition [24]. Similar to some class II IN mutants, viral particles produced 
during ALLINI treatment show very similar morphological defects of vRNPs 
mislocalization outside of the CA (Figure 6). A big fraction of virions that 
were formed under the ALLINI treatment has malformed and non-conical CA, 
while the fraction with the normal closed conical CA is markedly reduced. In 
the majority of these virions, even if the conical CA was assembled, the 
vRNPs were not incorporated inside it, but remained outside, between the CA 
and the viral envelope. IN also tends to be mislocalized, found outside of the 
CA or loosely attached to it. Furthermore, when IN is supplied to such 
virions, some of the malformed CA are replaced with the conical ones [25]. 
 
 
Figure 6: Comparison of viral particles with and without eccentric condensate and conical core. Taken 
from Fontana et al. 2015. [25] 
 
ALLINIs require both the IN and vRNA to induce the formation of vRNP 
eccentric condensate, as viral constructs that cannot express the vRNA did 
not yield a big fraction of eccentric aggregates when ALLINI-treated, 
compared with the normal virions that contain the vRNA [25]. This suggests 
that the disruption of IN-vRNA interaction causes the improper incorporation 
of vRNPs into the CA during the HIV-1 core morphogenesis, which may be 
the mechanism by which ALLINIs adversely affect virion maturation. 
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3.6 Reverse transcription blockade 
As already mentioned, the particles containing eccentric condensate are 
blocked at an early stage of reverse transcription in the target cells, even 
though they have all the components necessary for this process (vRNA 
genome, functional RT and normal NC-RNA levels). In the HIV-1 wild type, 
vRNA and IN cannot be degraded by the host cell metabolism and defense 
pathways because they are found inside the protective CA.  
Since this is not the case in the aberrant eccentric particles, vRNA and IN 
found outside of the CA are prematurely degraded upon the infection of the 
target cells, while RT remains active inside the CA lattice. This premature 
degradation of the vRNA genome, together with the spatial separation of RT 
from the eccentrically localized vRNPs, can explain this transcription defect 
of eccentric particles [26].  
      
3.7 Integrase - vRNA interactions 
Using the CLIP-seq techniques, it was determined that IN is directly 
bound to vRNA in virions (Figure 7) and that this binding is not uniform 
across the viral genome, as IN shows a strong preference for certain vRNA 
elements (Figure 8). For example, IN strongly binds the trans-activation 
response (TAR) element on vRNA, especially the TAR loop and 3-nt bulge of 
TAR [22]. 
 
 
Figure 7: AFM images of purified samples of IN alone, vRNA and IN+vRNA. The zoomed far-right 
image contains arrows pointing to the bright spots corresponding to the IN bound to vRNA. Taken 
from Kessel et al. 2016. [22]. 
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Figure 8: CLIP-Seq Analysis of IN binding sites on the vRNA genome from two independent 
experiments (the highest and middle graph), showing a nearly perfect overlap between IN binding 
sites (lowest graph). Taken from Kessel et al. 2016. [22]. 
 
 The surface exposed lysine residues (K264, K266, K269, K273) in the 
IN C-terminal domain (CTD) are believed to be the major sites of IN-vRNA 
interaction, as substitutions of these residues result in IN failing to bind 
vRNA. These mutations did not detectably affect other known IN functions 
nor processing of HIV-1 polyproteins by the protease, packaging of genomic 
RNA or particle release. However, the particles in which IN-vRNA interactions 
did not occur contained eccentric vRNP condensates and were noninfectious, 
as they fail to undergo the reverse transcription process in the target cells 
[22]. 
It appears that IN provides nucleation points by bridging separate vRNA 
molecules. It does not coat the vRNA, even when it is added in large excess 
- around four subunits of IN bind per one vRNA molecule [22]. In this way, 
IN effectively compacts the two copies of the viral genome, significantly 
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impacting the vRNP architecture, as well as ensuring the incorporation of 
vRNPs within the protective CA [22]. 
Because of these multiple IN-vRNA binding sites, IN multimers can 
efficiently bridge different segments of vRNA, promoting the vRNP 
compaction. Furthermore, the redundancy of structural elements along the 
vRNA on which the IN can bind allows the virus not to depend only on a 
single IN binding to a particular element on vRNA [22].  
When ALLINIs bind to the IN CCD domain, they promote multiple 
protein-protein contacts and induce aberrant IN multimerization (Figure 9). 
The vRNA interacting residues are then shielded by these multimers and 
unable to productively engage vRNA [22]. On the other hand, ALLINI-
induced aberrant IN multimerization does not affect the NC binding on vRNA, 
which means that vRNP condensation takes place idependently, before the 
core formation [26]. 
 
 
Figure 9: A molecular model of the IN tetramer with vRNA and ALLINI binding sites (K264, K266, 
K269, K273) shown as black spheres (left), and with the bound BI-B2 ALLINIs (right). Taken from 
Kessel et al. 2016. [22]. 
 
 
3.8 HIV-1 maturation model 
These discoveries showed that IN initiates vRNP incorporation into the 
CA, followed by the complete CA formation around them. When the 
maturation starts with the Gag-polyprotein processing by the protease [25], 
IN binds to the vRNA and ensures the packaging of the vRNA-NC complex 
inside the conical CA. ALLINIs, as well as some class II IN mutations, induce  
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aberrant IN multimerization which disrupts the binding of this enzyme 
to the vRNA. This leads to vRNPs being localized outside of the CA and to the 
formation of the noninfectious eccentric particles (Figure 10).   
 
 
 
Figure 10: Model for the role of IN in coordinating HIV-1 CA assembly and vRNP incorporation into 
the mature core. Taken from Fontana et al. 2015. [25]. 
 
3.9 ALLINI’s mechanism of action 
When the previously described results of ALLINI treatment of viral 
particles are taken into account, it is clear that ALLINIs are very promising 
new class of IN inhibitors, that could significantly enrich the already existing 
antiretroviral therapy. Even though there is a general idea on how ALLINIs 
work, there is still not a definite proposed mechanism model, like for the 
ALLINI precursors, INSTIs (Figure 11). When INSTIs are bound in the IN 
active site, their chelating moiety interacts with the two magnesium ions by 
moving the 3’-OH end of vDNA away from the active site by approximately 6 
A. The newly formed complex is then stabilized by the halobenzyl moiety, 
which is able to fit within a tight pocket and make the pi-stacking interaction 
with the C16 atom. These interactions lead to the removal of the 3'-OH 
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group from the active site, so it can not attack the target DNA [15]. This 
mechanism of action is shared by the two best known IN inhibitors, 
Raltegravir and Elvitegravir. 
Such a model still cannot be established for ALLINIs, for example BI-D 
and BIB-2 (Figure 12). The mechanism is most likely multimodal, combining 
their previously known ability to disrupt the IN-LEDGF/p75 interaction, 
together with their newly discovered ability to induce the aberrant IN 
multimerization. While this extends our understanding of virion maturation 
and how ALLINIs work, there is still a lot of research needed to be done to 
fully understand these processes. 
 
                     Elvitegravir                                         Raltegravir 
 
 
 
 
 
Figure 11: Structure and activity of Elvitegravir and Raltegravir. A halobenzyl group in a hydrophobic 
pocket (blue circle) and a triad that will chelate the two Mg2+ ions (red circle) are visible. Taken and 
adapted from ChemSpider. 
 
 
Figure 12: Chemical structures of two ALLINIs: BI-D and BIB-2. Taken from Fontana et al. 2015.  
[25] 
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4. Conclusion 
The aforementioned evidence presented from several research groups 
(Kessl et al., Madison et al., Jurado et al., Fontana et al.) strongly suggests 
that HIV-1 IN plays an important role during virion maturation. The 
possibility that IN ensures the proper packaging of vRNPs inside the conical 
CA comes as a very suprising and unexpected discovery, which enables the 
greater understanding of HIV-1 replication and maturation cycles, and 
demands an update of the current information regarding these processes.  
These discoveries also shed a light upon the mechanism of action of 
ALLINIs, which are already being used in clinical trials. These drugs seem to 
act mostly by blocking the IN-vRNA interaction, which is necessary for the 
proper vRNP incorporation inside the CA, causing their eccentric localization 
between the CA and the viral envelope. ALLINIs therefore prove themselves 
as a promising new type of IN inhibitors that could significantly enrich the 
HIV-1 antiretroviral therapy.  
These discoveries have a great perspective to be used not only in the 
development of ALLINIs, but also in the development of many other  HIV-1 
antiretroviral drugs, as a great number of them may follow a similar 
mechanism of action as ALLINIs. This constant development of antiretroviral 
therapy against HIV is extremely important due to a great number of viral 
mutations that arise during the virus replication cycle, which help it to 
acquire resistance against existing drugs. 
Even though this non-catalytic role of IN has a great potential to be 
used in the development of new types of IN inhibitors, a lot of details still 
need to be explained and clarified in the proposed new model of HIV-1 
maturation. Therefore, a lot of further research is required in order to fully 
understand HIV-1 maturation and replication processes and efficiently use 
this knowledge in the development of new anti-HIV drugs. 
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